Small Cap Voice

International Endeavors Corporation ("IEC") is a technology holdings company focused on Clean Energy, Crypto, and A.I.

Specializing in solar technology, battery storage, as well as clean energy crypto mining options for both on & off grid.

We're currently implementing EV2G / Bi-directional charging options, thus allowing you to use your electric vehicle as a means of a backup battery, or to sell power back to the grid.

In 2022 IDVV started to offer its clients a Clean Energy Crypto mining solution. Our Plug-n-Play mining rigs can be installed in existing or current systems and allows the option to sell power back to the grid or mine crypto currency with any power surplus.

In 2023 We acquired WITech and SF Corp as part of an expansion into the AI Sector. We are incorporating AI technology into our crypto offerings, and developing a platform for AI Content Marketing.

The Company currently is reporting its financial information on OTCMarkets.

Our filings can be seen at https://www.otcmarkets.com

SmallCapVoice.com Inc. (“SCV”) announces the availability of an interview with Jonathan Bates, chairman and CEO of BitMine Immersion Technologies, Inc. (OTC PINK:BMNR) (“the Company”), a technology company specialized in immersion technology for bitcoin mining.

With immersion technology, servers run fully submerged in a dielectric fluid that efficiently cools the machines. Removing heat in this manner allows for superior machine output and energy efficiency compared to conventional mining processes, ultimately improving yield and margins.

Speaking with SCV’s Stuart Smith, Bates provides an intriguing look at BitMine, which is likely the first specifically branded immersion public company, before diving into the state of the bitcoin industry and where the Company fits in.

“This is the future of mining. A lot of bigger companies ... have been touting their newly found expertise in immersion. Our team has been doing this for five years, even though this company is new,” Bates says. As discussed in the interview, his confidence in the Company and his team is further demonstrated by management’s decision to work for equity rather than draw a salary.

The interview also highlights BitMine’s recent milestones, operational goals for 2023, and other points of interest for the investment community.

“We represent a thematic play in the most cutting-edge version of bitcoin mining itself. Outside of the futures for bitcoin and ETFs, it’s the miners that are the public market representation,” he says. “Our play is a peripheral, smaller, potentially, ideally more upside way to thematically play bitcoin … If you line us up against the other miners, our marketcap is a lot smaller - thinner float and such - but I think we've got a lot of potential upside there.”

Nightfood Teams Up With Sonesta International Hotels Corporation to Offer Sleep-Friendly Snacks Across Multiple Hotel Brands

Eighth Largest Hotel Company in the US Launching Nightfood in Sonesta Select, Sonesta ES Suites and Sonesta Simply Suites Managed Properties

Nightfood is pioneering the category of sleep-friendly nighttime snacking.

Over 80% of Americans snack regularly at night, resulting in an estimated 700 million nighttime snack occasions weekly, and an annual spend on night snacks of over $50 billion. The most popular choices are ice cream, cookies, chips, and candy. Recent research confirms such snacks, in addition to being generally unhealthy, can impair sleep, partly due to excess fat and sugar consumed before bed.

Nightfood’s sleep-friendly snacks are formulated by sleep and nutrition experts to contain less of those sleep-disruptive ingredients, along with a focus on ingredients and nutrients that research suggests can support nighttime relaxation and better sleep quality.

The brand is currently focused on establishing widespread national distribution of Nightfood ice cream, cookies, and other snack formats in the hotel vertical.

Hotels are increasingly focused on supporting guest wellness. The Company believes one important way for hotels to do that is by offering sleep-friendly snacks in their grab-and-go lobby shops.

With an estimated 56,000 hotels across the United States, expanding distribution into a significant number of those hotels is expected to lead to profitability, consumer adoption of the nighttime snack category, and a strategically defensible position from which category leadership can be maintained.

Questions can be directed to [email protected]

By signing up at ir.nightfood.com, investors can receive updates of filings and news releases in their inbox.

SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Marc Hazout, president and CEO of SusGlobal Energy Corp. (OTCQB: SNRG) (“the Company”), to highlight a strategic appointment to its board of directors and recap significant corporate achievements.

As Leaders in the Circular Economy ®, SusGlobal is focused on reducing greenhouse gases and diverting organic waste streams from landfills, processing them into regenerative products such as fertilizer. Management’s mission is to grow the Company into a significant sustainable waste-to-energy and regenerative products provider and a trusted brand for fertilizer, soil, and aquaculture market.

To this accord, SusGlobal recently welcomed to its board of directors Bruce Rintoul, former senior vice president of operations of Veolia North America, where he led the transformation of U.S. and Canadian energy generation, water/wastewater management, hazardous waste, and environmental service businesses through operational and financial successes that resulted in the divestment of several Veolia businesses in North America.

Speaking to SCV’s Stuart Smith, Hazout explains the significance of his spot on SusGlobal’s board.

“Bruce is a very seasoned director. He's ICD designated, so that's important for the company; he's an independent director, so that's important too, certainly for our prospective uplifting,” he states. “Veolia is one of the biggest operators in North America – with a $20 billion market cap - in terms of these types of facilities. So, Bruce's addition, of course, will create significant shareholder value. There's no doubt in my mind, certainly with the direction we're going...we believe that this validates everything that we've been saying, and that is the intrinsic value of our environmental compliance approval licenses.”

The interview is chock full of additional information pertinent for existing and potential shareholders, such as the Company’s endorsement from Hall of Fame golfer Ernie Els and how his role as brand ambassador further supports the Company’s expansion initiatives, its progress toward uplisting to the Nasdaq, and more.

Principal Solar, Inc (OTC: PSWW) is a strategic investor in and acquirer of organizations and technologies that support next-generation opportunities in traditional, renewable, and clean energy sectors as well as an acquirer and operator of undervalued petroleum-producing properties.

For further information, please visit the Company’s website at www.pswwenergy.com.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Christina Moore, director of PawnTrust, a Dinewise Inc. (OTC:DWIS) company. Along with an impending name and ticker symbol change to reflect its focus, PawnTrust is fine-tuning its operations to disrupt the global pawn shop market.   

Speaking with SCV’s Stuart Smith, Moore explains how PawnTrust evolved from its financing origins to also become a data intelligence platform in the pawn and microlending vertical, a model under which the company achieved revenue growth of 400% in 2022 and could see revenues of more than $10 million in the year ahead.

As part of its expansion, Pawn Trust is adding experienced members to its management team and building a base of partner pawn shops and helping them pivot from their antiquated methods to grow their sales and market reach through PawnTrust’s digital marketplace.

“We look to have 1,000 pawn partners in 2023 and help them generate at least $120,000 in incremental sales per year by being on the Pawn Trust marketplace,” Moore says. “By doing that, which is very conservative, Pawn Trust will create revenue in excess of $10 million. At PawnTrust, we just throw the party. We bring the buyers and sellers together and we make our revenue through a fee that is charged to the pawn shop monthly. PawnTrust is a perfect example of necessity, meeting creativity.”

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the positive FDA feedback on BriaCell's pivotal study for lead clinical candidate Bria-IMT in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization. Successful completion of the pivotal study could be followed by a Biologics License Application submission and commercialization. Pivotal study's primary endpoint to be linked to survival improvement.

“We're treating patients with very advanced breast cancer,” Dr. Williams says. “These are patients who have failed at least two prior therapies, but most of them have failed on the average of six to seven prior attempts of therapy for their metastatic breast cancer. These are very difficult-to-treat patients. Their life expectancy is very short; many of them would otherwise be going on hospice.”

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FWB: CWY), to discuss the biotech company’s use of non-hallucinogenic psychedelic compounds to treat physical and mental health, including addiction.

Clearmind’s intellectual portfolio consists of seven patent families. Its lead candidate, CMND-100, is derived from 5-methoxy-2-aminoindane (MEAI), a psychoactive molecule that exerts a euphoric alcohol-like experience and a reduced desire to consume alcohol. CMND-100 is headed for clinical trials in early 2023 as a potential treatment for alcohol-use disorder (AUD), and Clearmind is also exploring the use of its MEAI-based compound to treat cocaine addiction and depression.

Earlier this month, Clearmind was granted a patent from the United States Patent and Trademark Office (USPTO) for the use of its proprietary MEAI as an alcoholic beverage substitute. Speaking with SCV’s Stuart Smith, Dr. Zuloff-Shani explains the global need for such treatment.

“The number of alcoholics is striking,” she says. “We're talking about millions around the world. Alcohol consumption contributes to 3 million deaths each year globally. It is the third leading, preventable cause of death in the U.S. and the yearly cost is enormous – around $200-$250 billion and that’s in 2010.”

Despite the statistics, Dr. Zuloff-Shani says that existing treatment options in this largely underserved market are largely ineffective. “You would think that a huge problem probably has a lot of treatments to offer,” she explains. “But it’s just the opposite. Since 1950, only three treatments were approved by the FDA. I cannot say that any of them are very effective or have no adverse events associated with it.”

In pre-clinical studies, however, MEAI has demonstrated promising efficacy in individuals who struggle with alcohol, helping to break the addiction cycle. Clearmind’s interest in the component came from the testimonials of people who purchased it to better manage their alcohol consumption.

As Dr. Zuloff-Shani explains in the interview, Clearmind paid attention to those experiences and the company selling the MEAI component online. Convinced of MEIA’s potential as a safe treatment option, it then acquired certain worldwide patents of MEAI used that information as an entry point for its own compound. Now, Clearmind is working on an Investigational New Drug (IND) application with the FDA as it advances toward clinical studies of MEAI next year.

“Usually when you develop a compound, you start from the other direction. You have an idea. You develop a compound and then you go to petri dishes and to animals, and finally you walk that you will have the same signal as, as you had in animals and in petri dishes in humans,” explains Dr. Zuloff-Shani. “Here, we are just doing the reverse process. We understand [MEAI] has the potential to be effective and safe … we decided that we want to do it in a safe place and take the FDA route.”

Smith then shifts the conversation toward Clearmind’s most recent developments and the strength of its management team, staff and scientific advisory board. Dr. Zuloff-Shani describes the structure of Clearmind’s operations and how it benefits corporate objectives and overhead.

“We have a very impressive staff in the company,” says Dr. Zuloff-Shani, who is well-versed in navigating regulatory pathways through her more than 20 years of experience in the biotech and pharmaceutical industries. “We don't have a lot of people, and this is by choice. We prefer to work in outsourcing because that enables us to manage our expenses better. On the other hand, it allows us to really collaborate in every field that we are dealing with.”

The interview concludes with what Clearmind expects to achieve in the New Year and how it plans to overcome the challenges associated with advancing toward clinical trials.

“The most important milestone we need to hit on 2023 is this IND application … this is really a major event in any company. We expect to have two clinical sites: one in the United States and one in Israel. So, it will be two applications to do different regulatory borders, asking the permission to start clinical trials, and then of course to start a clinical trial,” says Dr. Zuloff-Shani. “And then I hope that you interview me in December next year and I will tell you that we are now at the last stages of the study or reaching completion of the study.”

CEO, Cliff Emmons, and COO, Karen McNemar discuss the recently announced financial results for its third quarter ended September 30, 2022.

Cliff Emmons, CEO of IIOT-OXYS, Inc. (Oxys) stated, "We're pleased to announce that we kept our revenue promise for the quarter ended September 30th, 2022. As predicted, third quarter revenue exceeded that in second quarter. This makes two consecutive quarters of revenue, which the Company hasn't done since before the pandemic. We are pleased that the momentum of the second quarter's revenue continued into the third quarter and we expect it will continue through the fourth quarter. We also expect revenue for the second half of 2022 will exceed that generated in the first half of 2022. In total, we expect that total revenue for 2022 will be approaching 2019 levels. We continue to gain traction with strategic partners, customers, and potential customers in our key two markets: Smart Manufacturing / Industry 4.0 and Structural Health Monitoring (SHM). These are both high growth markets. Market research shows the worldwide Industry 4.0 market in 2021 was $64.9 billion USD and is projected to be $165.5 billion USD by 2026 (20.6% CAGR)1. Also, the worldwide Structural Health Monitoring industry was $2.0 billion USD in 2021 and will reach $4.0 billion USD by 2027 (CAGR of 14.6%)2. Through our collaborations with Aretas Sensor Networks, we have access to a third market, Indoor Air Quality Monitors, which was estimated at $3.7 billion USD in 2020 and projected to reach $6.4 billion USD in 2027, growing at 8.2% CAGR3."

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss three key achievements that support the Company’s continued growth. The Company recently announced positive initial efficacy data in its 2021-2022 cohort of 12 advanced breast cancer patients. Disease control, tumor shrinkage, and potential survival benefit were observed amongst 12 patients in the Phase I/IIa clinical study of Bria-IMT in combination with Incyte’s retifanlimab.

Bria-IMT regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell’s recent 12 patient cohort in advanced breast cancer. The study, recently awarded U.S. Food and Drug Administration ("FDA") fast track designation, continues with additional clinical data forthcoming.

The regimen remains well tolerated as recently reported in Phase I evaluation.

70% of patients showed either disease control or progression-free survival (PFS) benefits compared with their last therapy.

Prior to enrollment, the 12 patients in the cohort had already been unsuccessfully heavily pre-treated with at least 2 prior therapy regimens, further underscoring BriaCell’s positive patient outcomes.